Teligent Inc. (NASDAQ:TLGT) dropped 0.9% on Monday . The stock traded as low as $7.60 and last traded at $7.73, with a volume of 58,081 shares trading hands. The stock had previously closed at $7.80.

TLGT has been the subject of several recent analyst reports. Zacks Investment Research upgraded shares of Teligent from a “hold” rating to a “strong-buy” rating and set a $6.25 target price for the company in a research note on Wednesday, May 11th. Raymond James Financial Inc. initiated coverage on shares of Teligent in a research note on Wednesday, June 22nd. They issued a “strong-buy” rating and a $11.00 target price for the company. TheStreet upgraded shares of Teligent from a “sell” rating to a “hold” rating in a research note on Thursday, June 23rd. Finally, JMP Securities initiated coverage on shares of Teligent in a research note on Wednesday, June 29th. They issued a “hold” rating for the company. Four research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $9.42.

The company has a 50 day moving average of $8.16 and a 200-day moving average of $6.40. The company’s market capitalization is $409.89 million.

Teligent (NASDAQ:TLGT) last issued its quarterly earnings data on Thursday, July 28th. The company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.04. During the same quarter in the prior year, the company posted ($0.05) earnings per share. The company earned $17.14 million during the quarter, compared to analyst estimates of $16.03 million. The business’s revenue was up 92.8% compared to the same quarter last year. Analysts predict that Teligent Inc. will post $0.05 EPS for the current fiscal year.

Teligent, Inc, formerly IGI Laboratories, Inc, is a specialty generic pharmaceutical company. The Company markets and sells generic injectable pharmaceutical products under its own label in the United States and Canada. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.